

SCIENTIFIC PROGRAM
33RD ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY

Wednesday (22nd May 2019)

08:45-09:45 N.R. Datta (CH): Meta-analysis of clinical trials with hyperthermia	
09:45-10:45 J. Crezee (NL): Hyperthermia heating devices	
10:45-11:15 Coffee	
11:15-12:15 H. Gröll (D): Opportunities of HIFU for thermal therapy	
12:15-13:15 Lunch	
	12.30-13.30 PIK Room Int. J. of Hyperthermia meeting
13:15-14:15 T. Samaras (USA): Magnetic fluid hyperthermia: Advances and challenges for its translation to the clinic.	
14:15-15:15 S. Scheidegger (CH): Modelling HT-RT: BED and transient biological dose equivalent TBDE	
	14.00-16.30 PIK Room ESHO Board meeting
15:15-15:45 Coffee	
	15.00-16.45 KIER Room PTHO General Meeting
15:45-16:45 R. Kanaar (NL): Molecular effects of hyperthermia	
17.00-17.35 Opening Ceremony	
Speech congress president	
Speech congress v-president	

Speech congress secretary	
Speech ESHO president	
17:35-18:55 Plenary Session	
17:35-18:15 Z. Vujaskovic (USA): Protons and hyperthermia: early clinical results	
18:15-18:55 S. Bodis (CH): Building an international forum to boost hyperthermia research	
19.00-20.30 Exhibitors Area Cocktail	

Thursday (23rd May 2019)

08:30-10:15 Session 1 Hyperthermia Quality Assurance	
H. Dobsicek Trefna (S): Quality assurance guidelines for hyperthermia	
SP1 Johannes Crezee - ESHO Quality Assurance guidelines for Interstitial Hyperthermia	
SP2 Sergio Curto - Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial?	
SP3 Gerard van Rhoon - QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D and 3D techniques.	
SP4 Massimiliano Zanoli - Optimized Helmet Applicator Design for Child Brain-Tumor Hyperthermia	
SP5 Tom Paessler - Comparison of electro-quasistatic and FDTD calculation methods for modeling of capacitive hyperthermia	
SP6 Redi Poni - Inverse source method for element position optimization in modular systems for deep regional hyperthermia	
SP7 Petra Kok- SAR or temperature-based treatment planning as predictor for temperature changes after phase-amplitude steering during locoregional hyperthermia	
SP8 Tomas Drizdal - Standardization by a Universal Deep Hyperthermia Treatment Planning System	
10:15-10:45 Coffee	

10:45-12:15	
Session 2 Hyperthermia and immunotherapy	
U. Gaipl (D): Immunomodulation by hyperthermia in combination with radiotherapy (20 minutes)	
SP1 A-J. Donaubauer (D; M. Hader to present) - Immunomonitoring of patients with anal carcinoma treated with deep regional hyperthermia in combination with standard radiochemotherapy - first results of the HYCAN trial.	
SP2 Andras Szasz - Immune-effects with local hyperthermia	
SP3 Daniel Sousa - The reduction of the neutrophil / lymphocyte ratio (NLR) is associated with a complete response and disease-free survival in patients with non-invasive bladder cancer treated with intravesical neoadjuvant chemohyperthermia	
SP4 Henryk Mikołaj Kozłowski - The effect of hyperthermia on Iscador-treated macrophages.	
SP5 Stefaan Van Gool - Can we monitor Immunogenic Cell Death (ICD) induced with modulated electrohyperthermia and oncolytic virus injections ?	
12:15-13:30	
Lunch	
13:30-15:00	
Session 3 Tumor biology	
M. Horsman (DK): Hyperthermia: the optimal treatment to overcome tumor hypoxia	
SP1 Peter Hamar - Differential effects of modulated electro-hyperthermia on slow and fast progressing triple negative breast cancers and the effects of treatment protocol	
SP2 Mathias Weyland - Co-evolving model parameter search using cell survival and time-resolved comet data: A holistic view on the synergistic effect of hyperthermia and radiotherapy	
SP3 Marloes IJff - Hyperthermia combined with PARP1-inhibition as radiosensitizer in cervical cancer cells by affecting two DNA DSB repair pathways	
SP4 Timo L.M. ten Hagen - Thinking out of the nanoparticle: Externally triggered smart drug delivery systems demand chemotherapeutics with kinetics superior for local delivery.	
SP5 Niloy Ranjan Datta - Does hyperthermia clinically alter the α/β ? Insights	

from thermoradiotherapy vs. radiotherapy trials	
15:00-15:30 Coffee	
15:30-17:00 Session 4 Chemo-radiosensitization	
A. Kukielka (PL): Combined interstitial radiotherapy with interstitial hyperthermia	
SP1 Oliver Szasz - Molecular basis of modulated electro-hyperthermia combination with radio- and chemo-therapies	
SP2 Enzo Scutigliani - Improving Hyperthermia-Based Anti-Cancer Treatments by Modulation of the Heat Shock Reponse	
SP3 Gertrúd Fórika - Elevated apoptosis and tumor stem cell destruction in a radioresistant pancreatic adenocarcinoma cell line when radiotherapy is combined with modulated electro-hyperthermia	
SP4 Roxan Helderman - Institutional variations in Hyperthermic Intraperitoneal Chemotherapy	
SP5 Elming Pernille - Can the combination of hyperthermia with low LET radiation have an equivalent anti-tumor effect as seen with high LET radiation alone?	
17:00-18:30 Award Session	18:30-19.30 PIK Room ESHO General Assembly
Int. J. Hyperthermia Award	
ESHO young investigator Awards	
ESHO/Pyrexar Awards introduction	
ESHO/Pyrexar Award winner presentation	
20.00-00.30 Gala Dinner	

Friday (24th May 2019)

08:45-10:15 Session 5 Ongoing Clinical Studies	
L. Wyrwicz (PL): Hyperthermia in Poland	
SP1 Xinrui Zhang - Focused ultrasound-induced hyperthermia as radiosensitizer for glioblastoma, prostate cancer and head and neck cancer cell lines	
SP2 M Adelina Costa - Radiotherapy combined with Hyperthermia in the treatment of recurrent cancer of the head and neck region. Impact in early response and quality of life.	
SP3 Akke Bakker - Correlation between thermal dose and tumor control/ hyperthermia associated toxicity in recurrent breast cancer treated with thermoradiation	
SP4 Joao Moreira-Pinto - Evolution of Local-Regional and Whole-Body Hyperthermia in Portugal	
SP5 Panagiotis Apsotolou - Susceptibility to hyperthermia treatment through CTCs study	
10:15-10:45 Coffee	
10:45-12:15 Session 6 FLASH poster presentations	
12:15-13:30 Lunch	
13:30-15:30 Session 7 Recent clinical trials	
R. Fietkau (D): Erlangen University: Results of RT+HT clinical trials	
SP1 Emanuel Stutz - Proton therapy and hyperthermia in bulky, treatment-resistant extra-abdominal desmoid tumours	
SP2 Markus Notter - Combined wIRA-hyperthermia and repeat re-irradiation (re-re-RT) in the management of re-recurrences of locally recurrent breast cancer	
SP3 Leila Khalafi - Hyperthermia and radiation induced MR diffusion changes	

in brain glioma tumour treatment	
SP4 Carrie Minnaar - Effects of modulated electro-hyperthermia on disease control and 3 year disease-free survival in locally advanced cervical cancer patients: Preliminary results	
SP5 Niloy Ranjan Datta - Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study	
SP6 Rüdiger Wessalowski - Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer	
SP7 S. Bodis (CH) - New clinical strategies	
15:30-16:00 Coffee	
16:00-17:30 Session 8 MR-based hyperthermia	
T. Niendorf (D): Progress of MR-guided thermal intervention for brain tumors	
SP1 Iva Vilas Boas-Ribeiro - Potential impact of MR-only treatment planning for MR guided deep pelvic hyperthermia	
SP2 Lukas Sebeke - Thermal Therapy of the Porcine Pancreas in-vivo using MR-Guided HIFU	
SP3 Paul F Turner - MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms	
SP4 Gennaro G. Bellizzi - Design and validation of the MRcollar: the first clinical grade MR-guided head and neck applicator	
SP5 Peter Wust - Physical rationale and empirical data about mEHT as a low resource setting to treat brain tumors	
17:30-18:00 Closing Ceremony	

Saturday (25th May 2019)

Workshops in Warsaw Marie Curie Memorial Cancer Institute